B + L options license for compound to treat DES

Article

 

Montreal, Canada and Madison, NJ-Bausch + Lomb has acquired an option to license MIM-D3 and developed by Mimetogen Pharmaceuticals Inc. an investigational compound currently in Phase II development for the treatment of dry eye syndrome (DES).

MIM-D3 has the potential to be the first in a new class of agents called TrkA agonists, according to Mimetogen. MIM-D3 stimulates the production of mucin, vital for the protection and overall health of the ocular surface. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies including the potential to improve neural function, which may improve corneal sensitivity and integrity.

Phase II study results for MIM-D3 demonstrated that the use of MIM-D3, dosed bid, results in consistent improvements across multiple dry eye signs and symptoms with no safety or tolerability issues. A Phase III study is scheduled to begin before the end of 2013, which will be conducted by Ora Inc.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.